|
|
Usana Health Sciences Inc (USNA) |
|
Price: $38.4200
$0.33 
0.866%
|
| Day's High:
| $39.135
| Week Perf:
| 6.43 %
|
| Day's Low: |
$ 38.15 |
30 Day Perf: |
0.31 % |
| Volume (M): |
46 |
52 Wk High: |
$ 60.90 |
| Volume (M$): |
$ 1,767 |
52 Wk Avg: |
$47.49 |
| Open: |
$38.58 |
52 Wk Low: |
$36.05 |
|
|
| Market Capitalization (Millions $) |
736 |
| Shares
Outstanding (Millions) |
19 |
| Employees |
1,788 |
| Revenues (TTM) (Millions $) |
875 |
| Net Income (TTM) (Millions $) |
55 |
| Cash Flow (TTM) (Millions $) |
32 |
| Capital Exp. (TTM) (Millions $) |
15 |
Usana Health Sciences Inc
USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron
W. Wentz, Ph.D. We develop and manufacture high-quality, science-based nutritional
and personal care products with a primary focus on promoting long-term health
and reducing the risk of chronic degenerative disease. In so doing, we are committed
to continuous product innovation and sound scientific research. We have operations
in 20 markets worldwide, where we distribute and sell our products by way of
direct selling. We have chosen the direct selling distribution method as we
believe it is the most conducive to meeting our vision as a company, which is
improving the overall health and nutrition of individuals and families around
the world. Additionally, we are subject to the various laws and regulations
in the United States, China, and the other markets in which we operate with
respect to the products that we sell and to our method of distribution.
Company Address: 3838 West Parkway Blvd. Salt Lake City 84120 UT
Company Phone Number: 954-7100 Stock Exchange / Ticker: NYSE USNA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Usana Health Sciences Inc
Usana Health Sciences Inc (NYSE: USNA) recently released its financial results for the first quarter of 2024, signaling a concerning downward trend in its performance. Despite the company's optimistic outlook for the fiscal year, the decrease in earnings per share (EPS), revenue, and net profits raise doubts about its ability to compete in the increasingly competitive legal cannabis sector.
Earnings Decline:
In the first quarter of 2024, Usana Health Sciences Inc experienced a significant decrease in earnings compared to the previous year. EPS declined by -9.47% to $0.86 per share, down from $0.95 per share in the same quarter of the previous year. Additionally, EPS decreased by -0.63% from $0.87 per share in the previous quarter, highlighting a troubling trend.
|
| Usana Health Sciences Inc
Despite a slight decrease in revenue during the October to December 2023 period, Usana Health Sciences Inc (USNA) managed to raise its earnings per share (EPS), showing significant growth in profit. The company reported a surge of 30.06% in profit per share to $0.87, while revenue fell by -2.722% to $221.76 million year on year.
Comparing these results with the prior financial reporting period, Usana Health Sciences Inc demonstrated impressive growth. EPS soared from $0.59 per share, and revenue advanced by 4.195% from $212.84 million. This shows that the company is continuing to increase its profitability, even in the face of slightly lower revenue.
Furthermore, Usana Health Sciences Inc highlighted its improving profit margins, with net margin rising to 7.56% and operating margin edging up to 10.92% during the October to December 2023 period. These figures indicate the company's ability to control costs and maximize its profitability.
|
| Usana Health Sciences Inc
My Experience and Analysis of Usana Health Sciences Inc's Financial Results
As a financial analyst and avid follower of the stock market, I have closely examined the latest financial results of Usana Health Sciences Inc and I am here to provide some insight into what these numbers could mean for the company and its shareholders.
In the fiscal third quarter of 2023, Usana Health Sciences Inc experienced a significant decline in income. The company's income fell by -24.36% to $0.59 per share compared to $0.78 per share a year ago. This is certainly a cause for concern, as investors always hope to see consistent growth in a company's income. Additionally, the income also faded by -33.71% from $0.89 per share from the preceding financial reporting period.
|
| Usana Health Sciences Inc
The latest financial report from Usana Health Sciences Inc paints a concerning picture for the company's performance. Both revenue and net income have witnessed a significant decline, causing investors to raise concerns about the stock's future prospects. In this article, we analyze the key figures from the company's recent fiscal period and shed light on the challenges faced by Usana Health Sciences Inc.
Revenue Plummets:
During the most recent fiscal period, Usana Health Sciences Inc's revenue suffered a substantial decline of 12.823% year on year. Comparing the figures from the same three months a year earlier, revenue decreased from $272.87 million to $237.88 million. This downward trend indicates a potential struggle in maintaining consistent financial growth.
|
| Usana Health Sciences Inc
USANA Health Sciences Inc, a global nutritional company headquartered in Utah, reported impressive financial results for the first quarter of 2023. The company saw a revenue increase of 6.455% to $248.36 million, compared to $233.30 million during the same time period in the previous year.
Earnings per share (EPS) also showed a significant increase, jumping by 21.79% to $0.95, compared to $0.78 in the prior year reporting period. Revenue advanced by 8.949% from the previous period, while EPS soared by 42.77% from $0.67 per share.
The company's net earnings also showed year-on-year growth, increasing by 23.14% from $14.929 million in the first quarter of 2022 to $18.383 million in the first quarter of 2023.
USANA Health Sciences Inc accredited its improving profit margins for these impressive results. The company's net margin rose to 7.4%, and operating margin edged up to 10.81%. While operating earnings only improved by 18.63% to $26.845 million, these margins suggest a strong performance in the long run.
|
| Per Share |
Current |
| Earnings (TTM) |
2.86 $ |
| Revenues (TTM) |
45.66 $
|
| Cash Flow (TTM) |
1.68 $ |
| Cash |
17.35 $
|
| Book Value |
26.73 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
2.86 $
|
| Revenues (TTM) |
45.66 $ |
| Cash Flow (TTM) |
1.68 $ |
| Cash |
17.35 $
|
| Book Value |
26.73 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Direct Selling |
|
 99.22 % |
of total Revenue |
| All other |
|
0.78 % |
of total Revenue |
| Asia Pacific total |
|
80.15 % |
of total Revenue |
| Greater China |
|
54.26 % |
of total Revenue |
| Southeast Asia Pacific |
|
16.63 % |
of total Revenue |
| North Asia |
|
9.26 % |
of total Revenue |
| Americas and Europe |
|
19.85 % |
of total Revenue |
| China |
|
49.38 % |
of total Revenue |
| United States |
|
10.17 % |
of total Revenue |
| South Korea |
|
9.07 % |
of total Revenue |
| |
On July 24 2024 the Usana Health Sciences Inc provided following guidance
nnUSANA Health Sciences Releases Financial Results for the Second Quarter of 2024nn
On July 24, 2024, USANA Health Sciences, Inc. (NYSE: USNA), headquartered in Salt Lake City, revealed its financial performance for the second quarter that concluded on June 29, 2024. The company provided insights into its fiscal projections for the year, aiming to set clear expectations for investors and stakeholders.
In the recently reported quarter, USANA generated net sales totaling $213 million, which reflects a decline from the $238 million reported during the same quarter in the previous year, Q2 2023. Additionally, the company's diluted earnings per share (EPS) fell to $0.54, compared to $0.89 in Q2 2023...
|
|
|
4.79%